Business ❯ Healthcare

Clinical Trials

Drug Development Phase 3 Trials Phase 2 Trials Duchenne Muscular Dystrophy Regulatory Approvals Product Development Drug Approval Phase 3 Studies FDA Approval Autoimmune Diseases CHAMPION-AF Trial Drug Approval Process Access Programs Phase III Trials Patient Cohorts Drug Efficacy Partnerships Outsourcing Technology Neurotechnology Product Performance Evidence Generation Therapeutic Areas Oncology Drug Trials Regulatory Affairs Patient Treatment Phase 1 Studies ARTEMIS Phase 3 Trial Pipeline Development Operational Efficiency Research and Development Diabetes Research AI Innovations

Abeona Posts $8.7 Million Q1 From ZEVASKYN as Patient Treatments and Sites Expand

Early sales suggest the launch can grow without stretching the balance sheet.

Capricor Outlines Daramyocell’s FDA Review and Launch Prep as Distributor Dispute Looms

Axsome Reports 57% Q1 Sales Jump as FDA Clears Auvelity for Alzheimer’s Agitation

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

Boston Scientific Slumps to 52-Week Low After Watchman Trial Jitters and Downgrade

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Kynam Trims Syndax Stake With $8.18 Million Q4 Sale Disclosed in SEC Filing

Tenon Medical Posts Record 2025 Revenue as SImmetry+ Wins FDA Clearance

Biofrontera Reports Record 2025 Revenue of $41.7 Million and Best-Ever Q4 at $17.1 Million

Eli Lilly Prepares €15 Billion Abivax Offer, Eyes Next Wave of Weight-Loss Drugs

AnaptysBio CMO Trims Stake After Option Exercise as Director Reports Separate Sale

MPM BioImpact Exits MBX, MoonLake, Crinetics in Q3, SEC Filing Shows

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Arcutis Turns First Profit on Zoryve Surge, Lifts Outlook as Stock Jumps

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

Takeda Strikes $11 Billion-Plus Oncology Deal With Innovent, Pays $1.2 Billion Upfront

Eupraxia Selects 8 mg Dose After Strong EoE Signals, Expands Phase 2b Trial

S&P 500 Gains 1% on Tesla Robotaxi Debut and Merger Speculation; Supermicro Shares Plunge